<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306900</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-030-002</org_study_id>
    <nct_id>NCT04306900</nct_id>
  </id_info>
  <brief_title>TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers</brief_title>
  <official_title>Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tizona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tizona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39
      enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP)
      and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and
      promote anti-tumor immune response.

      This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and
      anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard
      chemotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of study subjects experiencing adverse events (AEs), dose-limiting toxicities, and serious adverse events (SAEs). Safety profile will be assessed through laboratory evaluations, vital signs, and physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>ORR is defined as the proportion of subjects with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>DoR will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>PFS is measured from documentation of progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Cycles 1-4 (each cycle is 21-28 days)</time_frame>
    <description>Serum concentrations of TTX-030 will be tabulated</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Combo 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab plus mFOLFOX6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab plus docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus mFOLFOX6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus budigalimab (selected tumors evaluated in expansion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, budigalimab and mFOLFOX6</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030, budigalimab and docetaxel</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030 and mFOLFOX6</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TTX-030 and budigalimab</intervention_name>
    <description>Dose and schedule per protocol</description>
    <arm_group_label>Combo 4</arm_group_label>
    <arm_group_label>Combo 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:

          1. Age 18 years or older, is willing and able to provide informed consent

          2. Histologically confirmed diagnosis of unresectable or metastatic solid tumor
             malignancy in selected tumor types

          3. Life expectancy &gt; 12 weeks

          4. ECOG performance status of 0-1

        Abbreviated Exclusion Criteria:

          1. History of allergy or hypersensitivity to study treatment components. Patients with a
             history of severe hypersensitivity reaction to any monoclonal antibody.

          2. Use of investigational agent within 28 days prior to the first dose of study treatment
             and throughout the study

          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive
             therapy

          4. History of severe autoimmune disease

          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tizona Therapeutics Inc</last_name>
    <phone>888-585-2990</phone>
    <email>clinicaltrials@tizonatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocala Oncology Center PL</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjit Nirmalanandhan</last_name>
      <phone>352-547-1958</phone>
      <email>sanjit.nirmalanandhan@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Center Oncology Hematology West P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays, M.A. CCRC</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center and Research Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <phone>901-683-0055</phone>
      <email>afletcher@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Line</last_name>
      <phone>615-329-7478</phone>
      <email>Cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-580-9521</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric (gastroesophageal cancer)</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>CD39</keyword>
  <keyword>Adenosine Pathway</keyword>
  <keyword>Immunotherapy Immuno-oncology</keyword>
  <keyword>PD-1 Checkpoint Inhibitor</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Budigalimab</keyword>
  <keyword>ABBV-181</keyword>
  <keyword>TTX-030</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

